½ÃÀ庸°í¼­
»óǰÄÚµå
1378698

°£Áú¼º ¹æ±¤¿° Ä¡·áÁ¦ ½ÃÀå : ¾àǰ Á¾·ùº°, À¯Çüº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°

Interstitial Cystitis Drugs Market, By Drug Class, By Type, By Route of Administration, By Distribution Channel, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è °£Áú¼º ¹æ±¤¿° Ä¡·áÁ¦ ½ÃÀåÀº 2023³â 2¾ï 3,490¸¸ ´Þ·¯¿¡ ´ÞÇϰí, ¿¹Ãø ±â°£(2023-2030³â) µ¿¾È 6.9%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º¸°í¼­ ´ë»ó ¹üÀ§ º¸°í¼­ »ó¼¼
±âÁØ ¿¬µµ 2022³â 2023³â ½ÃÀå ±Ô¸ð 2¾ï 3,490¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2018-2021³â ¿¹Ãø ±â°£ 2023-2030³â
¿¹Ãø ±â°£ÀÇ CAGR 6.90% 2030³â ½ÃÀå ±Ô¸ð ¿¹Ãø 3¾ï 7,560¸¸ ´Þ·¯
±×¸² 1. °£Áú¼º ¹æ±¤¿° Ä¡·áÁ¦ ¼¼°è ½ÃÀå Á¡À¯À²(%), ¾àÁ¦ Ŭ·¡½ºº°, 2023³â
Interstitial Cystitis Drugs Market-IMG1

°£Áú¼º ¹æ±¤¿°(IC)Àº ÅëÁõ¼º ¹æ±¤ ÁõÈıºÀ¸·Îµµ ¾Ë·ÁÁ® ÀÖÀ¸¸ç, ¹æ±¤°ú ±× ÁÖº¯ °ñ¹Ý ºÎÀ§¿¡ ¹Ýº¹ÀûÀÎ ºÒÆí°¨°ú ÅëÁõÀ» À¯¹ßÇÏ´Â ÁúȯÀÔ´Ï´Ù. Áõ»óÀº »ç¶÷¸¶´Ù ´Ù¸£¸ç, °°Àº »ç¶÷ÀÌ¶óµµ Áõ»óÀÌ ´Ù¸¦ ¼ö ÀÖ½À´Ï´Ù. ¹æ±¤°ú °ñ¹Ý ºÎÀ§¿¡ °æ¹ÌÇÑ ºÒÆí°¨, ¾Ð¹Ú°¨, ¾ÐÅë ¶Ç´Â ½ÉÇÑ ÅëÁõÀ» ´À³¥ ¼ö ÀÖ½À´Ï´Ù. Áõ»óÀ¸·Î´Â Àý¹Ú´¢, ºó´¢, ¶Ç´Â ÀÌ·¯ÇÑ Áõ»óÀÌ º¹ÇÕÀûÀ¸·Î ³ªÅ¸³¯ ¼ö ÀÖ½À´Ï´Ù. ÅëÁõÀº ¹æ±¤ÀÌ ¼Òº¯À¸·Î ä¿öÁö°Å³ª ¼Òº¯ÀÌ ºñ¿öÁö¸é¼­ °­µµ°¡ º¯ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿©¼ºÀÇ °æ¿ì ¿ù°æ Áß Áõ»óÀÌ ¾ÇÈ­µÇ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. Áú ¼º±³ ½Ã¿¡µµ ÅëÁõÀ» ´À³¥ ¼ö ÀÖ½À´Ï´Ù.

°£Áú¼º ¹æ±¤¿°°ú ÅëÁõ¼º ¹æ±¤ ÁõÈıºÀº ¹æ±¤º®¿¡ ¿°ÁõÀÌ »ý°Ü ÈäÅͰ¡ »ý±â°í µüµüÇÏ°Ô º¯ÇÒ ¼ö ÀÖ½À´Ï´Ù. Çѳª±Ë¾çÀº ¹æ±¤º®¿¡ »ý±ä Âõ¾îÁø ÇǺΠ¹ÝÁ¡À¸·Î IC ȯÀÚÀÇ 10%¿¡¼­ ¹ß°ßµÇ¸ç, IC¿Í PBS ȯÀÚ Áß ÀϺδ ¹æ±¤¿¡ ¼Òº¯ÀÌ Àß °íÀÌÁö ¾Ê¾Æ ¹è´¢ Ƚ¼ö°¡ Áõ°¡ÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ

°£Áú¼º ¹æ±¤¿° ȯÀÚ Ä¡·á¿¡ ´ëÇÑ ¿¬±¸ °³¹ßÀÌ È°¹ßÇØÁö¸é¼­ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 4¿ù 10ÀÏ ½ºÀ§½º ·ÎÀÜÀÇ ´ëÇк´¿øÀÎ Centre Hospitalier Universitaire Vaudois´Â ½ºÀ§½º º£¸¥¿¡ À§Ä¡ÇÑ ´ëÇк´¿ø ¿¬±¸Áø°ú ÇÔ²² °£Áú¼º ¹æ±¤¿° ¹× ÅëÁõ¼º ¹æ±¤ ÁõÈıº ȯÀÚÀÇ ¼ö¼ú Àü °æ±¸¿ë ¸é¿ª¿µ¾çÁ¦(IN)°¡ ¼ö¼ú ÈÄ ÇÕº´Áõ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡Çϱâ À§ÇÑ Àӻ󿬱¸¸¦ ½ÃÀÛÇÑ´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ¿¬±¸´Â ÇöÀç 3»ó ´Ü°è¿¡ ÀÖÀ¸¸ç Àû±ØÀûÀ¸·Î ȯÀÚ¸¦ ¸ðÁýÇϰí ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • ÀÌ º¸°í¼­´Â ¼¼°è °£Áú¼º ¹æ±¤¿° Ä¡·áÁ¦ ½ÃÀåÀ» »ó¼¼È÷ ºÐ¼®Çϰí 2022³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2023-2030³â)ÀÇ ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¦½ÃÇÕ´Ï´Ù.
  • ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®ÀÇ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ÆÄ¾ÇÇϰí, ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ ÁÖ¿ä ÀλçÀÌÆ®µµ Á¦°øÇÕ´Ï´Ù.
  • ¼¼°è °£Áú¼º ¹æ±¤¿° Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ¼º°ú ¹× Àü·«°ú °°Àº ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë ¹× ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼°è °£Áú¼º ¹æ±¤¿° Ä¡·áÁ¦ ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ÁøÀÔÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚ´Â ¼¼°è °£Áú¼º ¹æ±¤¿° Ä¡·áÁ¦ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú °¡Á¤

  • Á¶»ç ¸ñÀû
  • °¡Á¤
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

    • ½ÃÀå ¿ªÇÐ
  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
    • ¿µÇ⠺м®
    • ¿ª»çÀûÀÎ ·Îµå¸ÊÀ» ¼ö¹ÝÇÏ´Â ÃÖ±ÙÀÇ ½Å¾à ¹ß¸Å
    • ¿ªÇÐ
    • ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
    • Àμö¿Í Çù¾÷
    • ±ÔÁ¦ ½Ã³ª¸®¿À
    • ÁÖ¿ä ¹ßÀü
    • PEST ºÐ¼®

Á¦4Àå ¼¼°èÀÇ °£Áú¼º ¹æ±¤¿° Ä¡·áÁ¦ ½ÃÀå - COVID-19ÀÇ ¿µÇ⠺м®

    • °æÁ¦Àû ¿µÇâ
    • COVID-19ÀÇ ¿ªÇÐ
    • ¼ö¿ä¿Í °ø±Þ¿¡ ´ëÇÑ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ °£Áú¼º ¹æ±¤¿° Ä¡·áÁ¦ ½ÃÀå, ¾àÁ¦ Ŭ·¡½ºº°, 2018-2030³â

  • ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦
  • »ïȯ°è Ç׿ì¿ïÁ¦
  • ÆæÅä»ê Æú¸®¼³ÆäÀÌÆ® ³ªÆ®·ý(¿¤¹Ì·Ð)
  • µð¸ÞÆ¿ ¼³Æø»çÀ̵å(DMSO)
  • ±âŸ(Ç×È÷½ºÅ¸¹ÎÁ¦ µî)

Á¦6Àå ¼¼°èÀÇ °£Áú¼º ¹æ±¤¿° Ä¡·áÁ¦ ½ÃÀå, À¯Çüº°, 2018-2030³â

  • ºñ±Ë¾ç¼º
  • ±Ë¾ç¼º

Á¦7Àå ¼¼°èÀÇ °£Áú¼º ¹æ±¤¿° Ä¡·áÁ¦ ½ÃÀå, Åõ¿© °æ·Îº°, 2018-2030³â

  • °æ±¸
  • ¹æ±¤³»

Á¦8Àå ¼¼°èÀÇ °£Áú¼º ¹æ±¤¿° Ä¡·áÁ¦ ½ÃÀå, À¯Åë ä³Îº°, 2018-2030³â

  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦9Àå ¼¼°èÀÇ °£Áú¼º ¹æ±¤¿° Ä¡·áÁ¦ ½ÃÀå, Áö¿ªº°, 2018-2030³â

  • ºÏ¹Ì
  • ¹Ì±¹
  • ij³ª´Ù
  • À¯·´
  • ¿µ±¹
  • µ¶ÀÏ
  • ÀÌÅ»¸®¾Æ
  • ÇÁ¶û½º
  • ½ºÆäÀÎ
  • ·¯½Ã¾Æ
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áß±¹
  • Àεµ
  • ÀϺ»
  • ASEAN
  • È£ÁÖ
  • Çѱ¹
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ºê¶óÁú
  • ¸ß½ÃÄÚ
  • ¾Æ¸£ÇîÆ¼³ª
  • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿
  • GCC
  • À̽º¶ó¿¤
  • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
  • ºÏ¾ÆÇÁ¸®Ä«
  • Áß¾Ó¾ÆÇÁ¸®Ä«
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹

Á¦10Àå °æÀï »óȲ

  • ±â¾÷ °³¿ä
    • AbbVie Inc.
    • Hyloris Pharmaceuticals SA
    • TAGCyx Biotechnologies
    • KYORIN Pharmaceutical Co., Ltd.
    • PureTech Health
    • Vaneltix
    • Red Leaf Medical Inc.
    • Bayer AG
    • Eli Lilly and Co.
    • Johnson &Johnson(Janssen Pharmaceuticals)
    • Mylan NV(Viatris Inc.)
    • Perrigo Co. Plc
    • Pfizer Inc.
    • Seikagaku Corp.
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • ImprimisRx(Harrow Health, Inc.)

Á¦11Àå ¼½¼Ç

  • Âü°í¹®Çå
  • Á¶»ç ¹æ¹ý
ksm 23.11.29

The global interstitial cystitis drugs market is estimated to be valued at US$ 234.9 million in 2023 and is expected to exhibit a CAGR of 6.9% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 234.9 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 6.90% 2030 Value Projection: US$ 375.6 Mn
Figure 1. Global Interstitial Cystitis Drugs Market Share (%), By Drug Class, 2023
Interstitial Cystitis Drugs Market - IMG1

Interstitial cystitis (IC), also known as painful bladder syndrome, is a condition that results in recurring discomfort or pain in the bladder and the surrounding pelvic area. The symptoms can differ between cases and even within the same person.People may experience mild discomfort, pressure, tenderness, or intense pain in the bladder and pelvic area. Symptoms may include an urgent need to urinate, a frequent need to urinate, or a combination of these symptoms. Pain may change in intensity as the bladder fills with urine or as it empties. Women's symptoms often get worse during menstruation. They may sometimes experience pain during vaginal intercourse.

In interstitial cystitis or painful bladder syndrome, the bladder wall may be irritated and become scarred or stiff. Hunner's ulcers, patches of broken skin found on the bladder wall, are present in 10 percent of people with IC. While some people with IC or PBS find that their bladder cannot hold much urine, which increases the frequency of urination.

Market Dynamics

Rising research and development activities for the treatment of patients suffering from interstitial cystitis are expected to propel market growth over the forecast period. For instance, on April 10, 2023, Centre Hospitalier Universitaire Vaudois, a university hospital in Lausanne, Switzerland, in collaboration with researchers of the University Hospital based in Bern, Switzerland, announced the initiation of a clinical trial study to evaluate the impact of preoperative oral immunonutrition (IN) on post-operative complications in patients undergoing interstitial cystitis and painful bladder syndrome, which is currently in phase 3 and actively recruiting patients.

Key features of the study:

  • This report provides an in-depth analysis of the global interstitial cystitis drugs market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global interstitial cystitis drugs market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include AbbVie Inc., Hyloris Pharmaceuticals SA, TAGCyx Biotechnologies, KYORIN Pharmaceutical Co., Ltd., PureTech Health, Vaneltix, Red Leaf Medical Inc., Bayer AG, Eli Lilly and Co, Johnson & Johnson (Janssen Pharmaceuticals), Mylan NV (Viatris Inc.), Perrigo Co. Plc, Pfizer Inc., Seikagaku Corp., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. and ImprimisRx (Harrow Health, Inc.)
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global interstitial cystitis drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global interstitial cystitis drugs market

Interstitial Cystitis Drugs Market Detailed Segmentation:

  • By Drug Class:
    • Non-steroidal Anti-inflammatory Drugs
    • Tricyclic Antidepressants
    • Pentosan Polysulfate Sodium (Elmiron)
    • Dimethyl Sulfoxide (DMSO)
    • Others (Anti-histamines, etc.)
  • By Type:
    • Non-ulcerative
    • Ulcerative
  • By Route of Administration:
    • Oral
    • Intravesical
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Europe
    • Asia-Pacific
    • Latin America
    • Middle East & Africa
  • Company Profiles
    • AbbVie Inc.
    • Hyloris Pharmaceuticals SA
    • TAGCyx Biotechnologies
    • KYORIN Pharmaceutical Co., Ltd.
    • PureTech Health
    • Vaneltix
    • Red Leaf Medical Inc.
    • Bayer AG
    • Eli Lilly and Co.
    • Johnson & Johnson (Janssen Pharmaceuticals)
    • Mylan NV (Viatris Inc.)
    • Perrigo Co. Plc
    • Pfizer Inc.
    • Seikagaku Corp.
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • ImprimisRx (Harrow Health, Inc.)

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Type
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
    • Impact Analysis
    • Recent Drug Launch with Historic Roadmap
    • Epidemiology
    • Pipeline Analysis
    • Acquisition, and Collaborations
    • Regulatory Scenario
    • Key Developments
    • PEST Analysis

4. Global Interstitial Cystitis Drugs Market - COVID-19 Impact Analysis

    • Economic Impact
    • COVID-19 Epidemiology
    • Impact on Supply and Demand

5. Global Interstitial Cystitis Drugs Market, By Drug Class, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Non-steroidal Anti-inflammatory Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Tricyclic Antidepressants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Pentosan Polysulfate Sodium (Elmiron)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Dimethyl Sulfoxide (DMSO)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Others (Anti-histamines, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends

6. Global Interstitial Cystitis Drugs Market, By Type, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Non-ulcerative
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Ulcerative
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends

7. Global Interstitial Cystitis Drugs Market, By Route of Administration, 2018 - 2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends
  • Intravesical
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
    • Segment Trends

8. Global Interstitial Cystitis Drugs Market, By Distribution Channel, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

9. Global Interstitial Cystitis Drugs Market, By Region, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Type, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country/ Region, 2018-2030, (US$ Mn)
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

  • Company Profiles
    • AbbVie Inc.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • Hyloris Pharmaceuticals SA
    • TAGCyx Biotechnologies
    • KYORIN Pharmaceutical Co., Ltd.
    • PureTech Health
    • Vaneltix
    • Red Leaf Medical Inc.
    • Bayer AG
    • Eli Lilly and Co.
    • Johnson & Johnson (Janssen Pharmaceuticals)
    • Mylan NV (Viatris Inc.)
    • Perrigo Co. Plc
    • Pfizer Inc.
    • Seikagaku Corp.
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • ImprimisRx (Harrow Health, Inc.)

11. Section

  • References
  • Research Methodology
  • About us and Sales Contact
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦